As per MRFR Analysis, the Shingles Vaccine Market was valued at 3.64 USD Billion in 2023 and is projected to grow to 8.0 USD Billion by 2035, with a CAGR of 6.78% from 2025 to 2035. The market is driven by an aging population, rising awareness of shingles, and advancements in vaccine technology.
Key trends influencing the Shingles Vaccine Market include demographic shifts and technological innovations.
Merck and Co, Pfizer, VBI Vaccines, Daiichi Sankyo, Imunogenetics, Bavarian Nordic, AbbVie, Eli Lilly, Johnson and Johnson, Novartis, Regeneron Pharmaceuticals, Astellas Pharma, AstraZeneca, GlaxoSmithKline, Sanofi
The Shingles Vaccine Market is growing quickly because of important factors such as an older population and more people learning about the possible problems that shingles may cause. As the world's population becomes older, shingles is likely to become more common, which will increase the need for effective immunization options. Health campaigns and education initiatives are making people more aware of how important vaccination is, which is helping the market develop even more. Also, new technologies in vaccine development are making them safer and more effective, which is another important factor driving the market.
There have been a number of developments that have affected the Shingles Vaccine Market in the last few years. Telemedicine has made it easier for people to get healthcare, and more people may now get immunization advice from the comfort of their own homes. In addition, health officials across the globe suggest that older folks get vaccinated, which makes it easier for more people to become vaccinated. Investing more in healthcare infrastructure, especially in primary care settings, is also making it easier for people to get immunizations.
The market has opportunities to investigate, such as the chance to expand geographically into new areas where people do not know much about vaccines and cannot get to healthcare easily. Healthcare providers are becoming more interested in learning more about their patients' requirements and creating focused marketing. Better cooperation between commercial vaccine makers and public health groups might lead to more places to get vaccines and higher immunization rates throughout the world. This joint effort might help close health gaps and make sure that more people get immunizations, which will help control and stop shingles in the long run.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The increasing prevalence of shingles cases around the globe is a significant driver for the Shingles Vaccine Market Industry. According to the World Health Organization, globally, the incidence of shingles is estimated to be around 3.2 million cases each year. This rising statistic emphasizes the urgent need for effective vaccination strategies, particularly for older adults who are at higher risk.
The Centers for Disease Control and Prevention (CDC) notes that nearly 1 in 3 adults will develop shingles in their lifetime, which pushes the healthcare sector to prioritize vaccination programs. As public health initiatives aim to reduce the burden of this disease, the demand for shingles vaccines is expected to grow, thereby driving the market's advancement and expansion.
The rapid growth of the aging population globally serves as a crucial driver for the Shingles Vaccine Market Industry. According to the United Nations, the number of people aged 60 years and older is projected to double from 1 billion in 2020 to 2.1 billion by 2050. This demographic trend is significant as older individuals are particularly vulnerable to shingles, leading to increased healthcare spending on preventative measures like vaccines.
As governments and health organizations, such as the World Health Organization, shift focus towards older populations, the demand for shingles vaccines is anticipated to rise, consequently fueling market growth.
Innovations in vaccine technology are another critical driver for the Shingles Vaccine Market Industry. The introduction of adjuvanted formulations and recombinant technologies has improved the efficacy and safety profiles of shingles vaccines. For instance, the launch of Shingrix, an adjuvanted recombinant vaccine, has led to significant improvements in vaccination rates, demonstrating over 90% efficacy in clinical trials.
The U.S. Food and Drug Administration (FDA) and similar regulatory bodies around the world have recognized these advancements, prompting accelerated approvals for new vaccine candidates, which aligns with the sustained demand for better vaccination options. This technological advancement is expected to accelerate market growth as healthcare providers and patients alike seek more effective vaccination solutions.
Government initiatives that promote vaccination are vital catalysts for the Shingles Vaccine Market Industry. Many countries are rolling out public health campaigns to increase awareness about shingles and the importance of vaccination, particularly among older adults. For example, the United States also offers shingles vaccines for adults at no out-of-pocket cost under Medicare.
Programs initiated by health ministries globally emphasize the necessity of vaccination to mitigate the healthcare costs associated with shingles. With increasing support from governmental bodies and health organizations, the accessibility and affordability of shingles vaccines are improving, which will in turn bolster the market.
The Shingles Vaccine Market is projected to achieve a valuation of 3.89 USD Billion by 2024, with the Vaccine Type segment playing a crucial role in this growth. This segmentation includes key varieties such as Live Attenuated Vaccine, Recombinant Vaccine, and Subunit Vaccine, which contribute significantly to the market's overall performance. The Live Attenuated Vaccine segment has a notable market value of 1.56 USD Billion in 2024, which is expected to grow to 3.2 USD Billion by 2035, showcasing its majority holding in the marketplace. This type is highly significant as it utilizes weakened forms of the virus to stimulate an immune response, ultimately providing robust protection against shingles.
The Recombinant Vaccine segment, valued at 1.7 USD Billion in 2024, is anticipated to grow to 3.5 USD Billion by 2035. This segment is important due to its ability to produce a more targeted immune response without the risk of causing the disease, thereby appealing to a broader demographic, including those with compromised immune systems. On the other hand, the Subunit Vaccine is valued at 0.63 USD Billion in 2024, with expectations to reach 1.3 USD Billion by 2035. Although this segment holds the smallest share of the market, it plays a vital role by offering a safer alternative, as it consists only of specific pieces of the virus.
The overall trend in the Shingles Vaccine Market indicates a growing demand for safe and effective immunizations, driven by rising awareness about shingles and its complications globally. These vaccines are essential as they provide immunity to individuals aged 50 and older, particularly as the aging population increases, making vaccine development in this segment a significant opportunity for growth. The combined insights and financial offerings of these vaccines will shape the trajectory of the market, making it a focal point for industry stakeholders.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Shingles Vaccine Market is experiencing considerable growth, particularly across various age groups. In 2024, the market is projected to be valued at 3.89 billion USD, rising significantly by 2035. Within the age-specific segments, individuals aged 60-69 years and 70 years and above are of notable importance, as they are at an increased risk for shingles-related complications. This targets a demographic where the immune response starts to decline, making vaccination crucial. The age group of 50-59 years also holds a significant place, representing the earliest stage for recommended vaccination.
The key driver for this market is the increasing prevalence of varicella-zoster virus-related diseases, compounded by aging populations worldwide. As awareness of the availability and benefits of shingles vaccines rises, the market is set to witness enhanced demand, benefitting from initiatives aimed at promoting vaccination in these vital demographics. Additionally, as governments and health organizations prioritize public health measures, opportunities for growth in the Shingles Vaccine Market remain promising.
The Shingles Vaccine Market is experiencing significant growth within the Administration Route segment, which is fundamental for vaccine delivery effectiveness. As of 2024, the overall market is expected to be valued at approximately 3.89 billion USD, reflecting the increasing demand for effective patient administration routes. The market has been witnessing expansions with the subcutaneous, intramuscular, and intravenous solution administration methods gaining prominence due to their varied delivery efficiencies. Intramuscular administration, in particular, is noted for its widespread use and ability to induce a robust immune response, making it a favored choice in clinical settings.
Furthermore, the subcutaneous method, being less invasive, contributes to patient comfort and compliance, which is critical for vaccination drives. The intravenous route, while less common for shingles vaccination, offers a rapid onset of immune response and is significant in specific therapeutic scenarios. As the Shingles Vaccine Market data continues to evolve, understanding the Shingles Vaccine Market segmentation is paramount, given its potential to enhance immunization rates and overall healthcare outcomes. The market growth in this segment is supported by increasing awareness of shingles' complications and the importance of vaccination, creating opportunities for innovation and better patient outcomes.
The Shingles Vaccine Market revenue is experiencing notable growth, particularly within the End User segment, which encompasses Hospitals, Clinics, and Pharmacies. By 2024, the market is projected to reach a value of 3.89 billion USD, driven by the rising awareness regarding shingles and the increasing healthcare expenditure globally. Hospitals play a critical role, often serving as the primary institutions for vaccination services, while clinics offer accessibility to vaccinations for outpatients. Additionally, pharmacies have emerged as significant facilitators of vaccine distribution, providing convenience to patients seeking immunization.
The diverse distribution channels contribute to the overall market growth, as they improve the availability and awareness of shingles vaccines to a wider audience. This dynamic landscape presents both opportunities and challenges, including the need for effective supply chain management and educational initiatives to empower the public regarding the benefits of vaccination. As the market evolves, the Shingles Vaccine Market data shows that these End User categories will continue to be vital in enhancing vaccine accessibility and adoption rates, thereby addressing public health concerns worldwide.
The Shingles Vaccine Market revenue demonstrates significant regional differentiation, with North America leading in market valuation at 1.47 USD Billion in 2024 and anticipated growth to 3.05 USD Billion by 2035. This dominance can be attributed to rising awareness and healthcare access. Europe follows with a valuation of 1.21 USD Billion in 2024, increasing to 2.52 USD Billion in 2035, supported by strong healthcare frameworks and preventive measures. In South America, the market starts at 0.25 USD Billion in 2024 and is projected to grow to 0.5 USD Billion by 2035, highlighting a gradually increasing focus on vaccination programs.
The Asia Pacific region will see considerable development, increasing from 0.87 USD Billion in 2024 to 1.85 USD Billion in 2035, fueled by a growing aging population and health initiatives. Meanwhile, the Middle East and Africa's market valuation, starting at 0.09 USD Billion in 2024 and reaching 0.18 USD Billion in 2035, reflects ongoing challenges in healthcare delivery but shows potential for future growth. Overall, the Shingles Vaccine Market statistics indicate that North America and Europe hold majority shares, underscoring their pivotal roles in driving market growth through extensive public health strategies and vaccine accessibility.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Shingles Vaccine Market has become increasingly competitive due to the rising prevalence of shingles among older populations, leading to heightened demand for effective vaccination options. As healthcare systems across the globe emphasize preventive measures, the market is characterized by intense competition among established companies and new entrants alike.
Key players are focusing on innovation and expanding their product offerings to gain a competitive advantage while navigating regulatory approvals and market access challenges. Additionally, strategic partnerships, collaborations, and mergers are common as companies seek to leverage their strengths and enhance their market presence. As a result, understanding the competitive landscape is essential for stakeholders looking to thrive in this evolving market.
The Shingles Vaccine Market has seen significant developments in recent months. In October 2023, Merck & Co received approval from health authorities for its latest shingles vaccine, which is expected to boost market growth substantially. In terms of mergers, in March 2023, GlaxoSmithKline acquired a smaller biotech firm focused on infectious diseases, which included a shingles vaccine candidate in its pipeline.
This acquisition has positioned GlaxoSmithKline to enhance its portfolio within the shingles market. Additionally, there has been a greater focus on public awareness campaigns around shingles vaccination, particularly in the Americas and Europe, leading to increased vaccination rates and heightened consumer interest.
| Report Attribute/Metric | Details |
| Market Size 2023 | 3.64(USD Billion) |
| Market Size 2024 | 3.89(USD Billion) |
| Market Size 2035 | 8.0(USD Billion) |
| Compound Annual Growth Rate (CAGR) | 6.77% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Merck & Co, GlaxoSmithKline, |
| Segments Covered | Vaccine Type, Age Group, Administration Route, End User, Regional |
| Key Market Opportunities | Increasing geriatric population demand, Rising awareness about shingles prevention, Expanding healthcare access in emerging markets, Innovative vaccine formulations and delivery, Growing telehealth consultations for vaccines |
| Key Market Dynamics | Increasing elderly population, Rising awareness of shingles, Advancements in vaccine technology, Government vaccination programs, High healthcare costs. |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ):
The estimated market size of the Shingles Vaccine Market in 2024 is 3.89 USD Billion.
The projected market value for the Shingles Vaccine Market by 2035 is expected to reach 8.0 USD Billion.
The expected compound annual growth rate (CAGR) for the Shingles Vaccine Market from 2025 to 2035 is 6.77%.
North America holds the largest market share in the Shingles Vaccine Market in 2024, valued at 1.47 USD Billion.
The Asia Pacific region is expected to grow to 1.85 USD Billion in the Shingles Vaccine Market by 2035.
The Live Attenuated Vaccine is expected to dominate the Shingles Vaccine Market in terms of revenue, reaching 3.2 USD Billion by 2035.
Key players in the Shingles Vaccine Market include Merck & Co, and GlaxoSmithKline (GSK).
The market size for the Recombinant Vaccine in the Shingles Vaccine Market is expected to reach 3.5 USD Billion by 2035.
The Shingles Vaccine Market may face challenges such as increasing competition and regulatory hurdles impacting new product launches.
The Subunit Vaccine segment is projected to grow significantly, reaching 1.3 USD Billion by 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
